Type 2 diabetes and cardiovascular disease

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-28-2018 | Diabetic cardiomyopathy | Article

Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study

Rubio-Almanza M, Cámara-Gómez R, Hervás-Marín D et al. BMC Endocr Disord 2018; 18: 90. doi: 10.1186/s12902-018-0317-4

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-10-2018 | Retinopathy | Article

Diabetic retinopathy grade as a predictive marker of severity of cardiovascular disease and mortality: DIVERSE Study Group

Shah K et al. Int J Diabetes Dev Ctries 2018. doi: 10.1007/s13410-018-0699-x

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

11-02-2018 | Lifestyle interventions | Article

Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: One-year results of the PREDIMED-Plus trial

Salas-Salvadó J et al. Diabetes Care 2018: dc180836. doi: 10.2337/dc18-0836

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-16-2018 | Metabolic surgery | Article

Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity

Fisher DP et al. JAMA 2018; 320: 1570–1582. doi: 10.1001/jama.2018.14619

10-15-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

09-24-2018 | Atherosclerosis | Article

Prevention of atherothrombotic events in patients with diabetes mellitus: From antithrombotic therapies to new-generation glucose-lowering drugs

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2

09-05-2018 | Anti-hypertensive medications | Article

Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials

Leiter LA et al. Diabet Med 2018. doi: 10.1111/dme.13817

08-31-2018 | Retinopathy | Article

Could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

08-26-2018 | Cardiovascular disorders | Article

Effects of aspirin for primary prevention in persons with diabetes mellitus

The ASCEND Study Collaborative Group. N Eng J Med 2018. doi: 10.1056/NEJMoa1804988

08-26-2018 | Cardiovascular disorders | Article

Effects of n−3 fatty acid supplements in diabetes mellitus

The ASCEND Study Collaborative Group. N Eng J Med 2018. doi: 10.1056/NEJMoa1804989

08-24-2018 | Cardiovascular disorders | Review | Article

Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies

Bell DSH, Gonclaves E. Diabetes Obes Metab 2018. doi: 10.1111/dom.13512

08-23-2018 | Empagliflozin | Article

Real‐world opportunity of empagliflozin to improve blood pressure control in African Americans with type 2 diabetes: An NCDR® “research‐to‐practice” project from the Diabetes Collaborative Registry (DCR)

Arnold SV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13510

08-18-2018 | Bone health | Review | Article

Lifestyle management of diabetes: implications for the bone-vascular axis

Pieralice S et al. Curr Diab Rep 2018; 18: 84. doi: 10.1007/s11892-018-1060-y

08-17-2018 | Cardiovascular outcomes | Article

Trends and disparities in cardiovascular mortality among US adults with and without self-reported diabetes mellitus, 1988–2015

Cheng YJ et al. Diabetes Care 2018: dc180831. doi: 10.2337/dc18-0831